Format

Send to

Choose Destination
Stem Cell Res Ther. 2015 Apr 13;6:55. doi: 10.1186/s13287-015-0066-5.

Comparative analysis of human mesenchymal stem cells from bone marrow and adipose tissue under xeno-free conditions for cell therapy.

Author information

1
China Military Institute of Chinese Medicine, 302 Military Hospital, Beijing, 100039, China. chunyu327@163.com.
2
School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, China. chunyu327@163.com.
3
Beijing Institute of Life Science Translational Medicine Research Center, Beijing, 100085, China. chinastemcells@163.com.
4
Shandong Medicinal Biotechnology Centre, Shandong Academy of Medical Sciences, Jinan, 250000, China. virosome@163.com.
5
School of Pharmacy, Changchun University of Traditional Chinese Medicine, Changsha, 410208, China. xinxin_yang1980@126.com.
6
Jilin Vocational College of Industry and Technology, Jilin, 132013, China. jinglizhao2005@126.com.
7
China Military Institute of Chinese Medicine, 302 Military Hospital, Beijing, 100039, China. ringring12@126.com.
8
School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, China. ringring12@126.com.
9
The First Affiliated Hospital, Hebei North University, Zhangjiakou, 075000, China. 26609642@qq.com.
10
Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China. 13811647091@163.com.

Abstract

INTRODUCTION:

Mesenchymal stem cells (MSCs) are promising candidates for cell-based therapies. Human platelet lysate represents an efficient alternative to fetal bovine serum for clinical-scale expansion of MSCs. Different media used in culture processes should maintain the biological characteristics of MSCs during multiple passages. However, bone marrow-derived MSCs and adipose tissue-derived MSCs have not yet been directly compared with each other under human platelet lysate conditions. This study aims to conduct a direct head-to-head comparison of the biological characteristics of the two types of MSCs under human platelet lysate-supplemented culture conditions for their ability to be used in regenerative medicine applications.

METHODS:

The bone marrow- and adipose tissue-derived MSCs were cultured under human platelet lysate conditions and their biological characteristics evaluated for cell therapy (morphology, immunophenotype, colony-forming unit-fibroblast efficiency, proliferation capacity, potential for mesodermal differentiation, secreted proteins, and immunomodulatory effects).

RESULTS:

Under human platelet lysate-supplemented culture conditions, bone marrow- and adipose tissue-derived MSCs exhibited similar fibroblast-like morphology and expression patterns of surface markers. Adipose tissue-derived MSCs had greater proliferative potential than bone marrow-derived MSCs, while no significantly difference in colony efficiency were observed between the two types of cells. However, bone marrow-derived MSCs possessed higher capacity toward osteogenic and chondrogenic differentiation compared with adipose tissue-derived MSCs, while similar adipogenic differentiation potential wase observed between the two types of cells. There were some differences between bone marrow- and adipose tissue-derived MSCs for several secreted proteins, such as cytokine (interferon-γ), growth factors (basic fibroblast growth factor, hepatocyte growth factor, and insulin-like growth factor-1), and chemokine (stem cell-derived factor-1). Adipose tissue-derived MSCs had more potent immunomodulatory effects than bone marrow-derived MSCs.

CONCLUSIONS:

Adipose tissue-derived MSCs have biological advantages in the proliferative capacity, secreted proteins (basic fibroblast growth factor, interferon-γ, and insulin-like growth factor-1), and immunomodulatory effects, but bone marrow-derived MSCs have advantages in osteogenic and chondrogenic differentiation potential and secreted proteins (stem cell-derived factor-1 and hepatocyte growth factor); these biological advantages should be considered systematically when choosing the MSC source for specific clinical application.

PMID:
25884704
PMCID:
PMC4453294
DOI:
10.1186/s13287-015-0066-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center